Angie Drakulich

See Angie Drakulich's bio page.

FDA talks about the changing scope of regulatory science and its effect on drug reviews, site inspections, and overall approaches.

From time to time, it's important to take stock of the industry from both a retrospective and prospective point of view.

FDA talks about the changing scope of regulatory science and its effect on drug reviews, site inspections, overall approaches.

A look at the year's leaders in innovation strategy, including the top bio/pharmaceutical companies and award recipients from AAPS, PhRMA, and CPhI.

An interview with Eric M. Parker, Ph.D., Executive Director and Neuroscience Site Lead, Merck Research Laboratories, about the Merck BACE team's winning research.

PDA's strategic plan calls for maintaining valuable and effective relationships with global regulators.

Global tactics that incorporate online technologies and social media are reshaping disease response.

New England Compounding Center gets 483 after linked fungal meningitis outbreak.

At this week's AAPS 2012 Annual Meeting in Chicago, graduate students across the country are being honored for their research and work in bio/pharmaceutical innovation. Pharmaceutical Technology had the chance to talk with a few of the recipients.